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Abstract Curcumin, the yellow pigment from Curcuma longa,
has been shown to possess tumoricidal activity. We have earlier
reported the induction of apoptosis in AK-5, rat histiocytic cells
by curcumin leading to the inhibition of tumor growth in vivo. In
this study we have observed differential activation status in host
macrophages and NK cells induced by curcumin during the
spontaneous regression of subcutaneously transplanted AK-5
tumors. Closer scrutiny of the cytokine profile and nitric oxide
(NO) production by immune cells showed an initial down-
regulation of Th1 cytokine response and NO production by
macrophages, and their upregulation in NK cells, which picked-
up upon prolonged treatment with curcumin, culminating in a
stronger tumoricidal effect. These studies suggest that the host
macrophages and NK cells play an important modulatory role in
the remission of AK-5 tumor. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Curcumin, the active component of the rhizome Curcuma
longa possesses a wide spectrum of therapeutic applications
like anti-in£ammatory, antioxidant, bactericidal, antihelmintic
e¡ects and aids in reducing cholesterol levels [1^4]. This poly-
phenolic phytochemical is currently accepted as a potent anti-
cancer agent [5,6]. The tumoricidal e¡ect of curcumin has
been studied on a wide range of cell lines like mouse sarcoma
(S180), human colon cancer cells (HT-29), human kidney cell
line 293 and hepatocellular carcinoma (HepG2 cells) [7]. Cur-
cumin also showed antiproliferative activity on human breast
tumor MCF-7 cells [8].
Mechanisms of curcumin-mediated tumoricidal action are
attributed to the inhibition of protein tyrosine kinase activity,
protein kinase activity [9] and arachidonic acid metabolism
[7]. Curcumin caused growth arrest and apoptosis of B cell
lymphoma by downregulation of egr1, c-myc, bcl-XL, NF-kB
and p53 [10]. Curcumin was also found to downregulate
proin£ammatory cytokines like TNF-K, IL-1L and IL-8 [11].
However its inhibitory e¡ects on inducible nitric oxide syn-
thase (iNOS), an in£ammation-induced enzyme producing ni-
tric oxide (NO), may have opposite e¡ects as NO plays an
important role in carcinogenesis [11].
Curcumin also prevented tumor growth in animal tumor
models [12,13]. AK-5, a rat histiocytoma grows as ascites after
i.p. transplantation, killing 100% of the animals, but is re-
jected spontaneously when transplanted s.c. [14]. The s.c. tu-
mor remission is accompanied by upregulation of Th1 cyto-
kines, involvement of cell-mediated immunity and the
interplay of the free radicals [15]. We have earlier shown a
delay in tumor rejection after the administration of anticyto-
kine (anti IL-12 and anti IFN-Q) antibodies, mediated through
the downregulation of NO production and inhibition of cyto-
toxicity [16]. NK cells which act as e¡ectors in vivo have been
shown to induce apoptosis in AK-5 tumor cells through the
production of NO [17]. In the present investigation we show
that low doses of curcumin have a di¡erential e¡ect on NK
cells (leading to their activation) and on peritoneal macro-
phages (leading to their inactivation), in terms of NO produc-
tion and cytotoxic potential. However, prolonged exposure to
curcumin induced recovery of this e¡ect, ¢nally leading to a
faster remission of the AK-5 tumor.
2. Materials and methods
2.1. Animals and tumors
AK-5 tumor is maintained as ascites by continuous passage of
5U106 cells into the peritoneal cavity of a 6 weeks old inbred strain
of Wistar rats. Solid AK-5 tumors were obtained after subcutaneous
injection of 5U106 cells into 4^6 week old rats.
2.2. Curcumin injections
Animals were injected with AK-5 cells subcutaneously. One group
of 10 animals received a daily injection of 20 mg of curcumin i.p. until
day 20 after tumor transplantation. Tumor growth was measured with
a vernier calliper and the size was calculated using the formula 4/3 Z
a2b/2 where ‘a’ is the shortest diameter and ‘b’ is the longest diameter
in mm.
2.3. Collection of AK-5 serum
Curcumin treated/untreated tumor bearing animals on di¡erent
days after tumor transplantation (days 5, 10, 15, 20) were bled
through the retro-orbital plexus. The sera were separated by centrifu-
gation and stored at 320‡C until further use.
2.4. Preparation of macrophages
Curcumin-treated and untreated AK-5 tumor bearing animals (days
5, 10, 15, 20) were sacri¢ced and 20 ml of cold PBS containing hep-
arin (10 U/ml) was injected into the peritoneal cavity. The peritoneal
lavage was carefully aspirated out and placed at 4‡C. The cell suspen-
sion was centrifuged for 10 min at 800Ug to obtain a white pellet,
which was resuspended in IMDM supplemented with FCS (5%) and a
mixture of antibiotics (Gibco-BRL). Macrophages were allowed to
adhere for 2 h and the £oating cells were washed out. Macrophages
were cultured in IMDM for 24 h and the supernatants were collected
and stored at 370‡C for nitrite and cytokine estimations.
2.5. Preparation of NK cells
Splenocytes from normal, immune (AK-5 tumor rejected animals)
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and curcumin-treated animals on days 5, 10, 15 and 20 after tumor
transplantation were fractionated on a Ficoll-Hypaque gradient. The
lymphocyte fraction was plated in RPMI-FCS for 2 h to allow macro-
phage adhesion. The non-adherent cells were incubated with mAb
3.2.3 (speci¢c for NKR-P1 receptor, Endogene Inc., USA)-coated
Dynal magnetic beads, at a cell:bead ratio of 1:2 for 30 min. The
NK cells bound to the beads were separated using Detach-a-bead
(Dynal, Oslo, Norway). The purity of the cell preparations was tested
by £ow cytometry and the preparations containing more than 95%
positive cells were used in these experiments.
2.6. Cytokine estimations
Cytokines in the animal sera and culture supernatants were esti-
mated using an enzyme-linked immuno¢ltration assay (ELIFA, Pierce
Chemical Co.). The initial ligand solution (culture supernatant) was
bound to nitrocellulose membrane [18] and the membrane was
blocked with PBS^BSA solution followed by treatment with appro-
priate dilutions of anticytokine antibodies. The membrane was
washed and treated with horseradish peroxidase-conjugated secondary
antibody (1:3000, Boehringer-Mannheim, Germany). The unbound
antibody was removed by washing and the signal was produced on
the membrane by developing for peroxidase. The standard curves for
the cytokines were generated with pure murine cytokines obtained
from the National Institute of Biological Standards (Hertfordshire,
UK). Recombinant mIL-12 was a kind gift from Dr. U. Gu«bler,
Ho¡mann-La Roche.
2.7. NO estimation
The measurement of nitrite in the macrophage^NK cell culture
supernatants was an indirect indicator of NO released by the activated
cells. Macrophages were cultured for 16 h, whereas NK cells were
cocultured with AK-5 cells in the presence of anti AK-5 antibody at
an E:T ratio of 50:1 for 4 h. 100 Wl of the culture supernatants were
mixed with equal volume of Griess reagent and the absorbance was
read at 540 nm [19]. Standard curve for nitrite was generated using
NaNO3 (Sigma). AK-5 cells did not produce any NO under these
conditions.
2.8. Cytotoxicity assays
51Cr-labelled AK-5 cells were cocultured with peritoneal macro-
phages collected from curcumin treated/untreated AK-5 tumor bear-
ing rats (E:T = 10:1) for 18 h at 37‡C. Similarly, a cytotoxicity assay
was performed with immune, in vitro and in vivo curcumin-treated
NK cells. 51Cr-labelled AK-5 cells were cultured with NK cells in the
presence of anti AK-5 antibody (E:T = 50:1) for 4 h. The chromium
released into the supernatant was counted and the percentage cyto-
toxicity was calculated.
2.9. Curcumin treatment in vitro
Peritoneal macrophages from day 15 tumor bearing rats were
plated in 24 well plates (1U106 cells/well) and di¡erent concentrations
of curcumin were added (5, 10, 15, 20 WM) in vitro. The cells were
incubated for 18 h and the nitrite released in the culture supernatant
was measured using Griess reagent. Similarly, NK cells from normal
animals were cultured in the presence of di¡erent concentrations of
curcumin (5, 10, 15, 20 WM). After 18 h treatment, the cells were
washed with PBS and used for nitrite determination as described ear-
lier.
2.10. SDS^PAGE and Western blotting
Peritoneal macrophages and splenic NK cells collected from AK-5
tumor (s.c.) transplanted animals (untreated/treated with curcumin in
vivo) were washed and boiled in Laemmli’s bu¡er. The proteins were
resolved on 10% SDS polyacrylamide gel and transferred to nitro-
cellulose membrane [20]. The membrane was blocked with 3% PBS^
BSA, and incubated overnight at 4‡C with anti iNOS monoclonal
antibody (Transduction Laboratories, 1:2500). The blots were
washed, incubated with antimouse IgG coupled to AP and developed
with BCIP/NBT.
3. Results
3.1. E¡ect of curcumin on AK-5 tumor growth
We have studied the e¡ect of curcumin administered i.p. on
the growth of AK-5 tumor transplanted s.c. Curcumin (20
mg/animal) was administered daily up to day 20 after the
tumor transplantation. Curcumin-injected animals exhibited
larger tumors as compared to the positive controls (Fig. 1).
Maximum tumor size was attained by day 15 in both the
groups. However the tumors were rejected faster in the cur-
cumin-treated group after day 15 and the tumor size was
smaller than the positive control animals by day 20 after the
tumor transplantation.
3.2. E¡ect of curcumin in vivo
We have studied the e¡ect of in vivo administration of
curcumin on the cytotoxic activity as well as the production
of NO by the peritoneal macrophages and splenic NK cells.
3.2.1. Cytotoxic activity. Macrophages from control and
curcumin-treated animals were cocultured with AK-5 tumor
cells. Maximum cytotoxicity was achieved with day 15 tumor
transplanted macrophages and NK cells (Fig. 2). However,
macrophages from curcumin-treated animals possessed lower
cytotoxicity as compared to the controls (Fig. 2B). NK cells
on the other hand showed higher cytotoxicity against YAC-1
as well as AK-5 cells (ADCC) as compared to the immune
NK cells (positive control). Optimal NK cytotoxicity was ob-
served around day 15 (Fig. 2D).
3.2.2. NO production. The NO production pattern corre-
lated well with the cytotoxic activity of macrophages and NK
Fig. 1. E¡ect of curcumin on AK-5 tumor growth on di¡erent days.
Closed bars represent the control group whereas open bars represent
curcumin-treated animals (20 mg/animal/day). Values shown are
average of 10 animals per group.
Table 1
E¡ect of curcumin on the production of NO by macrophages and
NK cells in vitroa
Curcumin (WM) Nitrite concentration
Macrophages (WM/105 cells) NK (Wg/105 cells)
0.0 86.5 þ 4.8 0.42 þ 0.13
2.5 81.2 þ 6.5 0.71 þ 0.09b
5.0 67.9 þ 4.5b 0.86 þ 0.10b
10.0 59.1 þ 2.9b 0.91 þ 0.07b
20.0 51.9 þ 3.1b 0.68 þ 0.11
40.0 29.5 þ 2.7b N.D.
50.0 22.0 þ 2.3b N.D.
aPeritoneal macrophages were collected from day 15, AK-5 tumor
bearing animals and NK cells were prepared from normal rat sple-
nocytes. 105 cells were incubated with curcumin for 18 h. Culture
supernatants were tested for nitrite estimations. The values shown
are mean þ S.E.M. of two similar experiments. N.D. = not deter-
mined.
bP6 0.001 with respect to untreated controls.
FEBS 24197 6-10-00
S. Bhaumik et al./FEBS Letters 483 (2000) 78^82 79
cells after treatment with curcumin. Nitrite production by
curcumin-treated macrophages was lower up to day 15 after
tumor transplantation (Fig. 2A). However, curcumin-treated
NK cells produced higher quantities of nitrite as compared
to the untreated controls, the optimal levels being between
days 10 and 15 (Fig. 2C). These observations suggest suppres-
sion of macrophage cytotoxicity and NO production by cur-
cumin whereas in NK cells curcumin upregulated production
of NO with a corresponding increase in their cytotoxic activ-
ity.
3.3. E¡ect of curcumin in vitro
In order to con¢rm our in vivo observations, we tested
the e¡ect of di¡erent concentrations of curcumin on isolated
macrophages and NK cells. There was a dose dependent
inhibition of NO production by macrophages, whereas NO
production by NK cells increased with curcumin con-
centrations (Table 1), thus con¢rming our in vivo observa-
tions.
3.4. E¡ect of curcumin on the production of cytokines
We have earlier shown that cytokines like IL-2, IFN-Q [21],
IL-12 [22] and TNF-K [23] played a signi¢cant role in the
activation of host immune cells, which in turn participated
in the rejection of AK-5 tumor in syngeneic animals. In the
present study we have investigated the cytokine pro¢le in
animals after administration of curcumin on di¡erent days.
The production of IFN-Q, IL-12 and TNF-K increased with
tumor growth reaching the peak values between day 15 and 20
in the tumor-transplanted positive control animals (Fig. 3).
However, the production of these cytokines in curcumin-in-
jected animals was downregulated on days 5 and 10 after the
tumor transplantation. The levels of IFN-Q (Fig. 3A) and
IL-12 (Fig. 3C) were elevated signi¢cantly on days 15 and
20. The overall cytokine levels remained lower in the curcu-
min-treated animals as compared to the untreated controls.
TNF-K levels on the other hand remained lower throughout
the duration of this experiment in curcumin-administered an-
imals (Fig. 3B). We have also studied the release of IL-12 by
Fig. 2. E¡ect of curcumin on NO production (A and C) and cytotoxic activity (B and D) of macrophages and NK cells. A, B: Represent mac-
rophages (control a ; curcumin F) and C and D represent NK cells. C, D: The symbols shown are YAC1+iNK (8) ; YAC-1+cur NK (F) ;
AK-5+iNK (R) ; AK-5+iNK+KAK-5 (*); AK-5+cur NK (X); AK-5+cur NK+KAK-5 (b). The values shown are representative of three simi-
lar experiments.
Fig. 3. E¡ect of curcumin on cytokine levels in AK-5 tumor bearing animals. A: Shows serum IFN-Q. B: TNF-K. C: Serum IL-12. D: Shows
the IL-12 levels in the macrophage culture media on di¡erent days. Control (a) ; curcumin-treated (F). The values shown are representative of
three similar experiments.
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peritoneal macrophages in vitro. Macrophages from curcu-
min-injected animals secreted lower concentrations of IL-12
in the culture medium up to day 15 (Fig. 3D). However, day
20 macrophages produced more of IL-12 as compared to the
control cells (Fig. 3D).
3.5. Expression of iNOS in curcumin-treated macrophages and
NK cells
In order to con¢rm our earlier results pertaining to NO
production after the administration of curcumin in AK-5 tu-
mor bearing animals, we also studied the expression of iNOS
protein by Western blotting. There was upregulation of iNOS
expression in peritoneal macrophages from s.c. tumor bearing
animals (Fig. 4B, lanes 1, 3, 5 and 7). However, curcumin-
treated animals did not show any iNOS protein on days 5, 10
and 15 (lanes 2, 4 and 6), whereas on day 20 there was some
expression of iNOS observed (lane 8). The iNOS protein was
absent in day 5 NK cells, which was upregulated on days 10
and 15 (Fig. 4A, lanes 1, 3, 5). Curcumin treatment induced
the expression of iNOS in NK cells on day 5 (lane 2). The
level of iNOS expression on days 10 and 15 was not signi¢-
cantly di¡erent to the controls (lanes 4 and 6). These results
suggest a di¡erential e¡ect of curcumin on iNOS expression
by macrophages and NK cells.
4. Discussion
Alternative medicine for treatment of various diseases is
getting more popular. Because of limited scienti¢c evidences
and lack of mechanistic understanding it is not yet incorpo-
rated into the mainstream of medical care. However, alterna-
tive medicine is becoming an increasingly attractive approach
world-wide and much attention is being given for its system-
atic study and applications. Curcumin, a common dietary pig-
ment possesses a wide range of therapeutic utilities in tradi-
tional Indian medicine [1]. Its role in wound healing, urinary
tract disease, liver ailments, hepatitis are well documented, in
addition to its use as a cosmetic [1,3]. In addition, curcumin
exhibits a variety of pharmacological e¡ects including anti-
in£ammatory, anticarcinogenic and anti-infectious activities
[2,4,5].
In the present investigation, we have tried to elucidate over-
all immunological e¡ects of curcumin on AK-5 tumor growth
and regression in Wistar rats. Curcumin, a known antioxi-
dant, has been shown to inhibit activation of free-radical-ac-
tivated transcription factors like NF-kB and AP-1 where it is
identi¢ed as an antioxidant [9]. Also downregulation of iNOS
gene expression in activated murine macrophages is demon-
strated upon treatment with curcumin [24], yet, curcumin is
known to induce tumor cell apoptosis [13]. Thus downregula-
tion of NO production may prevent carcinogenesis on one
hand, whereas, overall suppression of free radical production
during the physiological process may encourage the develop-
ment of the tumor. On closer scrutiny, the AK-5-transplanted
animals showed an initial downregulation of NO production
and reduced cytotoxic capabilities in host macrophages (day 5
and 10) after curcumin treatment which led to the develop-
ment of larger size tumors (Fig. 1). At the same time however,
the NK cells showed progressive upregulation of NO produc-
tion and cytotoxicity (Fig. 2). The peritoneal macrophages
were probably a¡ected by the overall suppression of IFN-Q,
TNF-K and IL-12 levels as observed in the sera (Fig. 3). The
serum cytokine pro¢le was signi¢cantly downregulated during
the initial growing phase of the AK-5 tumor suggesting an
inhibitory e¡ect of curcumin administration. Curcumin-medi-
ated TNF-K downregulation has also been reported earlier
[25]. Kang and coworkers on the other hand, have reported
a downregulating e¡ect of curcumin on IL-12 production,
thereby aiding in Th1-cytokine-mediated diseases [26]. In the
present investigation we have also observed reduced IL-12
production in the sera and in the macrophage supernatants
collected from day 5 and 10 curcumin-treated animals as com-
pared to the control animals (Figs. 2 and 3). Curcumin-
treated animal macrophages showed very low NO production
and no detectable iNOS protein (Fig. 4B, lanes 2, 4). In NK
cells however, there was an upregulation of NO production
and iNOS protein (Fig. 4A). Surprisingly, the results reversed
from day 15 onwards, when a progressive upward trend in the
serum cytokine pro¢le, polarizing Th1 type response, as well
as macrophage-mediated IL-12 production on days 15 and 20
after curcumin treatment in AK-5 tumor bearing animals was
observed. There was also an increase in macrophage-mediated
cytotoxicity and NO production (Fig. 2).
Detectable levels of iNOS protein in day 15 and 20 macro-
phages were observed (Fig. 4B, lanes 6, 8). However, in NK
cells, there was a high level of NO production and the pres-
ence of iNOS protein from day 5 onwards with no signi¢cant
changes until day 20. A similar trend was observed by Brouet
and his group where curcumin downregulated the production
of iNOS proteins in LPS/IFN-treated RAW 264.7 cells after
6 h, whereas detectable levels of iNOS proteins were seen after
18 h [27]. These observations suggest that lower concentra-
tions of curcumin have an inhibitory e¡ect on macrophages
(i.e. on days 5 and 10) which is lost after sustained treatment
with curcumin over a longer period of time. The ultimate
e¡ect being the revival of Th1 cytokine response, production
of NO and increased cytotoxicity leading to the rejection of
the tumor.
Thus curcumin seems to be an interesting molecule possess-
ing anticancer activity. We have recently shown the generation
of reactive oxygen species after the treatment of the tumor
cells with curcumin, which in turn induced apoptosis in tumor
cells [28]. Thus curcumin, which has been reported to down-
regulate NO production in vitro, showed a di¡erential e¡ect
in vivo, where it induced activation of immune cells leading to
Fig. 4. E¡ect of curcumin on the iNOS expression by NK cells (A)
and macrophages (B). A: Lanes 1, control day 5; 2, curcumin day
5; 3, control day 10; 4, curcumin day 10; 5, control day 15; 6, cur-
cumin day 15. B: Lanes 1, control day 5; 2, curcumin day 5; 3,
control day 10; 4, curcumin day 10; 5, control day 15; 6, curcumin
day 15; 7, control day 20; 8, curcumin day 20.
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the regression of the tumor. These observations suggest a dual
e¡ect of curcumin on tumor cells, one directly by inducing
apoptosis and secondly through the activation of immune
cells.
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